Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

TDGF1 Antikörper

Der Kaninchen Polyklonal Anti-TDGF1-Antikörper wurde für ELISA, WB und IHC validiert. Er ist geeignet, TDGF1 in Proben von Human und Maus zu detektieren. Es sind 5+ Publikationen verfügbar.
Rockland
Produktnummer ABIN233828
Hersteller Produkt- Nr.: 600-401-997

Kurzübersicht für TDGF1 Antikörper (ABIN233828)

Target

Alle TDGF1 Antikörper anzeigen
TDGF1 (Teratocarcinoma-Derived Growth Factor 1 (TDGF1))

Reaktivität

  • 57
  • 21
  • 12
Human, Maus

Wirt

  • 36
  • 23
  • 2
  • 1
Kaninchen

Klonalität

  • 36
  • 25
Polyklonal

Konjugat

  • 27
  • 5
  • 5
  • 4
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Dieser TDGF1 Antikörper ist unkonjugiert

Applikation

  • 41
  • 20
  • 17
  • 14
  • 5
  • 4
  • 3
  • 3
  • 3
  • 2
  • 1
ELISA, Western Blotting (WB), Immunohistochemistry (IHC)
  • Hersteller Produkt- Nr.

    600-401-997

    Hersteller

    Rockland

    Verwendungszweck

    Cripto-1 TDGF1 Antibody

    Kreuzreaktivität (Details)

    This antibody is specific for human Cripto-1 protein.

    Produktmerkmale

    Synonyms: rabbit anti-Cripto 1 antibody, rabbit anti-Cripto-1 antibody, Cripto 1 growth factor antibody, Epidermal growth factor like cripto protein CR1 antibody, TDGF 1 antibody, Teratocarcinoma-derived growth factor 1, CRGF, TDGF1

    Aufreinigung

    This product was affinity purified from monospecific antiserum by immunoaffinity chromatography.

    Sterilität

    Sterile filtered

    Immunogen

    Immunogen: This affinity purified antibody was prepared from whole rabbit serum produced by repeated immunizations with a synthetic peptide corresponding to an internal sequence of human Cripto-1 protein.

    Immunogen Type: Conjugated Peptide

    Isotyp

    IgG
  • Applikationshinweise

    Immunohistochemistry Dilution: User Optimized

    Application Note: This affinity purified antibody has been tested for use in ELISA and western blotting.  Specific conditions for reactivity should be optimized by the end user.  Expect a band approximately 21 kDa in size corresponding to Cripto-1 by western blotting in the appropriate cell lysate or extract.  Cripto-1 is reported as a 188 amino acid protein with a molecular weight of 21.1 kDa.

    Western Blot Dilution: 1:1000

    ELISA Dilution: 1:105,000

    Other: User Optimized

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Liquid

    Konzentration

    0.66 mg/mL

    Buffer

    Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2

    Stabilizer: None

    Preservative: 0.01 % (w/v) Sodium Azide

    Konservierungsmittel

    Sodium azide

    Vorsichtsmaßnahmen

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Lagerung

    4 °C,-20 °C

    Informationen zur Lagerung

    Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.

    Haltbarkeit

    12 months
  • Ligtenberg, Witt, Galvez-Cancino, Sette, Lundqvist, Lladser, Kiessling: "Cripto-1 vaccination elicits protective immunity against metastatic melanoma." in: Oncoimmunology, Vol. 5, Issue 5, pp. e1128613, (2016) (PubMed).

    Strizzi, Margaryan, Gerami, Haghighat, Harms, Madonna, Botti, Ascierto, Hendrix: "Translational significance of Nodal, Cripto-1 and Notch4 in adult nevi." in: Oncology letters, Vol. 12, Issue 2, pp. 1349-1354, (2016) (PubMed).

    Tysnes, Satran, Mork, Margaryan, Eide, Petersen, Strizzi, Hendrix: "Age-Dependent Association between Protein Expression of the Embryonic Stem Cell Marker Cripto-1 and Survival of Glioblastoma Patients." in: Translational oncology, Vol. 6, Issue 6, pp. 732-41, (2014) (PubMed).

    Strizzi, Margaryan, Gilgur, Hardy, Normanno, Salomon, Hendrix: "The significance of a Cripto-1 positive subpopulation of human melanoma cells exhibiting stem cell-like characteristics." in: Cell cycle (Georgetown, Tex.), Vol. 12, Issue 9, pp. 1450-6, (2013) (PubMed).

    Malchenko, Galat, Seftor, Vanin, Costa, Seftor, Soares, Hendrix: "Cancer hallmarks in induced pluripotent cells: new insights." in: Journal of cellular physiology, Vol. 225, Issue 2, pp. 390-3, (2010) (PubMed).

  • Target

    TDGF1 (Teratocarcinoma-Derived Growth Factor 1 (TDGF1))

    Andere Bezeichnung

    TDGF1

    Hintergrund

    Background: This antibody is designed, produced, and validated as part of a collaboration with the National Cancer Institute (NCI) and is suitable for Cancer, Immunology and Nuclear Signaling research. Human Cripto-1 (CR-1), also known as Teratocarcinoma-derived growth factor 1 (TDGF1), is a member of the epidermal growth factor (EGF)-GFC family and has been implicated in both embryogenesis and carcinogenesis.  During early vertebrate development, CR-1 functions as a co-receptor for Nodal, a transforming growth factor b (TGFb) family member, and is essential for mesoderm and endoderm formation and anterior-posterior and left-right axis establishment.  In adult tissues, CR-1 is expressed at a low level in all stages of mammary gland development, and expression increases during pregnancy and lactation.  Over-expression of CR-1 in mouse mammary epithelial cells leads to their transformation in vitro, and when injected in mammary glands, CR-1 produces ductal hyperplasias.

    Gen-ID

    6997, 4507425

    UniProt

    P13385

    Pathways

    EGFR Signaling Pathway
Sie sind hier:
Chat with us!